All Oncology News

The CHMP has recommended pembrolizumab plus enfortumab vedotin-ejfv in frontline unresectable or metastatic urothelial carcinoma.

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.

Sara M. Tolaney, MD, MPH, discusses the transformation of treatments for patients with triple-negative breast cancer.

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.

NICE recommends pembrolizumab plus platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric or GEJ adenocarcinoma.

Atezolizumab administered before and following chemoradiation appeared to be safe and efficacious in unresectable stage III non–small cell lung cancer.

Should the FDA require that new trial design proposals for perioperative regimens for resectable NSCLC include adequate within trial assessment?

Richard Bleicher, MD, FACS, has been named 2023-2024 University of Texas MD Anderson Cancer Center Breast Surgical Oncology Fellowship’s Annual Distinguished Commencement Visiting Professor.

Health Canada has granted full approval to dostarlimab monotherapy for patients with recurrent or advanced dMMR/MSI-H endometrial cancer.

Donor fecal microbiota transplants increased the activity of immunotherapy in patients with GI cancers.

Bintrafusp alfa elicited responses in patients with recurrent/metastatic cervical cancer, warranting further exploration of TGF-β-targeted therapies.

The FDA has accepted the resubmission of a BLA for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Time-limited acalabrutinib plus obinutuzumab produced responses in treatment-naive chronic lymphocytic leukemia.

Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.

Blinatumomab added to consolidation chemotherapy led to a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Paolo Tarantino, MD, discusses questions about the optimal sequencing of antibody-drug conjugates in endocrine-refractory, HR-positive breast cancer.

Shubham Pant, MD, MBBS, discusses findings from the phase 2b HERIZON-BTC-01 study of zanidatamab in pretreated HER2-positive biliary tract cancer.

Eileen M. O'Reilly, MD, details how RAS-directed therapy could potentially change the pancreatic cancer landscape and highlights updated data in the space.

The FDA has accepted the new drug application for the new TLX007-CDx cold kit for the preparation of PSMA-PET imaging in patients with prostate cancer.

New START early-phase clinical trial site brings advanced cancer research to Northwell’s Cancer Institute, increases patient access

The incidence of ICANS and CRS post-CAR T-cell therapy decreased after 2 weeks in patients with DLBCL, supporting a reduction of the monitoring period.

An EHR-based prompt or “nudge” decreased the rates of sentinel lymph node biopsy among older patients with early-stage breast cancer.

Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.

Crofelemer did not improve the incidence of diarrhea in patients with solid tumors receiving targeted therapy.

Rituximab maintenance therapy following frontline bendamustine plus rituximab improved EFS, EFS2, and OS vs no maintenance therapy in patients with MCL.

Women with severe endometriosis are 10 times more likely to get ovarian cancer, compared to women who do not have the disease.

Iopofosine I 131 generated a major response rate of 56.4% in patients with relapsed/refractory Waldenström macroglobulinemia.

The FDA has accepted the resubmission of a BLA for remestemcel-L in pediatric steroid-refractory acute graft-vs-host-disease.

The ROR2-targeted ADC ozuriftamab vedotin has received FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

Vishal Patel, MD, FAAD, FACMS, highlights the evolving role of PD-1 inhibitors in the management of nonmelanoma skin cancers.